NovoCure Limited

NVCR

NASDAQ

Healthcare

Medical - Instruments & Supplies

Saint Helier, JE1,488 employeesnovocure.com

$10.55

-0.28(-2.63%)

Mkt Cap $1.2B

$10.03

$19.40

52-Week Range

At a Glance

AI-generated

8-K

NovoCure Limited announced positive topline results from the Phase 2 PANOVA-4 trial on March 26, 2026, meeting its primary endpoint with a 74.4% disease control rate (DCR) for Tumor Treating Fields therapy combined with atezolizumab, gemcitabine, and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma, versus 48% in historical control (p<0.001). This supports advancing TTFields therapy for metastatic pancreatic cancer.

$1.2B

Market Cap

$669M

Revenue

-$139M

Net Income

Employees1,488

Fundamentals

How The Business Makes Money

Revenue by Geography

US47.9%($1.1B)

International Markets24.8%($583M)

DE8.7%($205M)

FR6.1%($144M)

Other International Markets5.6%($132M)

JP4.3%($102M)

CN2.6%($60M)

Activity

What Changed Recently

Financial Results

Feb 25, 2026

Results of Operations and Financial Condition. On February 26, 2026, the Company issued a press release announcing certain financial results for the fiscal year

Financial Results

Jan 11, 2026

of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorp

Regulation FD

Mar 25, 2026

Regulation FD Disclosure. On March 26, 2026, the Company issued a press release announcing positive results from the Phase 2 PANOVA-4 trial of Tumor Treating Fi

Regulation FD

Feb 23, 2026

Regulation FD Disclosure. On February 2, 2026, the registrant's U.S. subsidiary, Novocure Inc. (the "Company") received a letter dated January 29, 2026 from the

Regulation FD

Feb 10, 2026

Regulation FD Disclosure. On February 11, 2026, the Company issued a press release announcing that that the U.S. Food and Drug Administration (FDA) has approved

Company Profile

CIK0001645113

ISINJE00BYSS4X48

CUSIPG6674U108

Phone44 15 3475 6700

AddressNo. 4 The Forum, Saint Helier, JE2 4UF, JE

SEC EDGAR